In combination with KL-6, the oncological markers CA 19-9, CA 125, and CEA correlate with the presence and severity of ILD in patients with RA (124) while serum HE4, a biomarker for ovarian cancer, may identify RA cases at risk for subclinical ILD (125). Here, MUC1 is linked to rheumatoid arthritis.